Area of research
Physiology · Immunology
Research interest
Research interests include Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Respiratory and Cough-Related Research, and Eosinophilic Esophagitis.
Alternative Splicing Is a Major Factor Shaping Transcriptome Diversity in Mild and Severe Chronic Obstructive Pulmonary Disease.
Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD
Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis
A genome-wide association study of chronic spontaneous urticaria risk and heterogeneity.
Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis
Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma
Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.
A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk
Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthma
Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma.
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
A genome-wide association study of chronic spontaneous urticaria risk and heterogeneity
Integrated systems modeling of severe asthma: Exploration of IL-33/ST2 antagonism.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection
Galectin-8 Is Upregulated in Keratinocytes by IL-17A and Promotes Proliferation by Regulating Mitosis in Psoriasis.
Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease
A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens
An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma
Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma.
IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma
Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab
The airway microbiome in patients with severe asthma: Associations with disease features and severity
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
LATE-BREAKING ABSTRACT: Serum IL-13 is a peripheral biomarker for Type 2 asthma
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production
Exploring the Effects of Omalizumab in Allergic Asthma
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge